text:
Guests at the Lyrath Estate Hotel are spoilt for choice with regards to their specialised Cocktail menu. Indulge in the popular Lyrath Signature Mojito, which include ingredients of white rum, fresh lime juice, fresh sugar cane juice, club soda and mint.
Why not ask your friends and family to contribute towards your dream honeymoon?
Order one of our gorgeous hotel directories.
Enter our draw to win a two-night bed and breakfast stay at Elba Estepona Gran Hotel & Thalasso Spa in Estepona, southern Spain.
Enter the draw


text:
I doubt these two former Denver players even made the trip to New York.
As for Renaldo Balkman, best of luck to TAZ in Denver and beyond. As a rookie, his was the jersey I wanted to get, but last year he did little for the Knicks, so I understand why Walsh pulled the trigger on this deal. If you're going to make an omelette, you have to break some eggs. Everyone knows we are fully stocked–if not overstocked–at the three.
Walsh isn't finished making deals this summer. The roster is back down to 15 with this move, but you have to think it could easily be 12 or 13 if you consider the Summer '08 buyout candidates: Malik Rose, Jerome James and Stephon Marbury. Stay tuned for more on those possibilities.
Speaking of Starbury, I heard he has a deal in place with Amazon.com should Steve and Barry's close their doors due to impending bankruptcy. I'm hoping someone comes in and buys up Steve and Barry's because I think they're doing noble work offering low-cost clothing and shoes to those who don't want to pay $140 for a pair of Nikes. It would be a shame if they have to close their doors.
Who knows? Maybe I'll rock the Wilson Chandler Ponys in 2008-2009. Just make sure they make them in Knicks Orange and Blue. Those start at about $60, I hear, or the price of 6.7 pairs of Starburys / Big Bens.

subset: commoncrawl


text:
The "mortgage clause" can mean people need the bank's OK before you make repairs... Read more
Companies handling flood insurance claims after Hurricane Sandy are being sued for fraud in federal court Read more
Agency also using the rate tables that were in effect prior to Biggert-Waters'... Read more
Louisiana senators press agency to speed up on a provision reversing rate hikes... Read more
As spring construction begins, new programs aim to keep workers in one piece. Read more
Some safety incentive plans could violate OSHA's reporting requirements. Does yours? Read more
Congressional battles over flood insurance result in a new law. Read more
The legislation holds flood insurance premium increases to 18% per year Read more
The vote could happen Thursday or Friday of this week, after all Read more
It's now up to the Senate to pass or modify the legislation. Read more


text:
50 Fresh JavaScript Tools That Will Improve Your Workflow
- By Jacob Gube
- June 21st, 2009
- 39 Comments
JavaScript is an integral part of the RIA revolution. JavaScript allows developers to create rich and interactive web interfaces and establishing asynchronous communication with servers for constantly up-to-date data without a page refresh.
Many things that were once accomplished using Flash objects can now be built using JavaScript – with the added benefit that it is free, typically more web and mobile accessible under most circumstances using best practices for development techniques, and without the need to use proprietary software for development.
Though JavaScript has been around for a while, new tools, techniques, and information are constantly being pumped out to continually push the technology into greater heights. In this article, we wish to share with you a huge list of fresh and new tools and resources that JavaScript developers will find useful and informative.
Here are a few other posts that you might find interesting:
Useful JavaScript Tools Link
Unit testing is an integral part of building high-performance and efficient web applications. John Resig (creator of jQuery library) and Jan Odvarko have developed an excellent Firefox/Firebug extension called FireUnit which gives developers logging and testing capabilities via a simple JavaScript API. For those interested in the tool, you should also read Odvarko's post detailing the usage of FireUnit5.
Sugar Test7
SugarTest makes it easy to write elegant and understandable JavaScript tests. Its API is inspired by both RSpec, Shoulda and jQuery. It works as a DSL running on top of JsUnitTest.
JS.Class: Ruby-style JavaScript9
JS.Class is a library designed to facilitate object-oriented development in JavaScript. It implements Ruby's core object, module and class system and some of its metaprogramming facilities, giving you a powerful base to build well-structured OO programs.
JSON Formatter and Validator11
The JSON Formatter was created to help with debugging. As data expressed as JSON is often written without line breaks to save space, it became extremely difficult to actually read it. This tool hopes to solve the problem by formatting the JSON into data that is easily readable by human beings.
Faux Console: Simulating a Firebug, Safari or Opera debugging in IE12
JS Bin13
JS Bin is a web application for testing and debugging JavaScript and CSS collaboratively. You input your source code and save it to a publicly-accessible URL which you can then share to your fellow developers or in social networking outlets like Twitter or Facebook groups. Be sure to check out the video introduction14 to see JS Bin in action.
PHP.JS is an open source project in which we try to port PHP functions to JavaScript. By including the PHP.JS library in your own projects, you can use your favorite PHP functions client-side.
Page Speed17
Page Speed, released by Google, is a Firefox/Firebug extension very similar to YSlow18 that evaluates your web pages for performance. Read more about Page Speed best practices to see what aspects of a web page are being evaluated. YSlow and Page Speed are based off Steve Souder's work19 (who worked for Yahoo! and now works for Google).
Spket IDE24
Spket is an excellent toolkit for JavaScript and XML development. It has a robust and intuitive GUI, and integrates with popular and powerful JavaScript/Ajax libraries such as Y!UI and jQuery. Its JavaScript Formatter25 feature gives you unparalleled control and standardization for you or your team's JavaScript code formatting standards.
Obtrusive JavaScript Checker27
Obtrusive JavaScript Checker, created by Robert Nyman, is a tool for finding inline JavaScript on web pages. It highlights elements that have inline JavaScript properties and provides a summary report when you mouse over them. The tool is available as a Firefox extension28 or a Greasemonkey script29.
Highlight.js highlights syntax in code examples on blogs, forums and other web pages. The tool works automatically: it finds blocks of code, detects a language and highlights it accordingly.
Javascript Compressor32
Javascript Compressor is a web-based tool for compressing your JavaScript to reduce their file sizes. It works by removing unnecessary characters (such as extra tabs and spaces). Developers who use the tool to compress their code can also use the decoding feature to uncompress their source code. It also obfuscates your code, making it harder to read – which can be desirable if you want to delay prying eyes from analyzing your publicly-available code base.
Firediff is a Firefox/Firebug extension that allows you to track changes in the DOM and CSS. By logging these changes, you can gain information about how web applications work, and what elements (and what properties) are being altered by way of DOM manipulation.
RockStar Web Profiler36
RockStar Web Profiler (aka Razor) logs and profiles information about client-side performance. It provides developers with a console for analyzing the data gathered by the tool. Check out the RockStar Web Profiler presentation to get an overview of its many awesome features.
bookmarklet maker37
This plain and simple web tool allows you to create JavaScript-based bookmarklets. Usage is simple: simply copy and paste your source code into it and it will output the processed code in the lower pane.
Tiny JS
Tiny JS is an online directory of small but powerful plugins for popular JavaScript/Ajax libraries (MooTools, jQuery, and YUI at the moment). Its aim is to hunt down and feature lightweight plugins that give you a lot of bang for the buck.
Glimmer is an interactive design tool for incorporating slick JavaScript-based animation effects using the jQuery library. Glimmer comes with a wizard-style user interface which can reduce the amount of coding that you have to write manually.
A testing environment for JavaScript that runs on IE 6+, Firefox 2+ and Safari 3+. The tool shows differences between expected value and actual value, displays the failed line exactly and supports conditional execution. Released under GNU and available for free download40.
CodeRun Code Search
CodeRun's Code Search tool lets you search and view user-submitted Ajax, PHP, and .NET source code. Once you've found a script or project that you're interested in, you can edit it via their web-based IDE without having to download the project locally.
BaseJS: A Mobile (Safari) Javascript Framework41
a simple, lightweight framework created specifically for Mobile Safari (perfect for iPhone development).
MochaUI is a web-based tool for building web application interfaces built on top of the MooTools JavaScript framework. Jump right in by taking MochaUI for a spin in their demo page43.
Utility Libraries and Components for JavaScript Link
narwhal is a server-side JavaScript library following the ServerJS45 standard. Developers can create and share "packages" for website widgets, site features, programming patterns, in a similar fashion as PEAR46 for PHP.
uploadify is a useful jQuery plugin for dealing with file uploads. It's powered by a simple PHP script for handling the server-side stuff. Be sure to check out the uploadify demos48 to see the plugin in action.
Blackbird lets you log messages in JavaScript using a simple and intuitive JS-based API. The library also provides you with an attractive console GUI for viewing and analyzing messages. No more annoying alert() functions to see your objects' contents (which can be frustrating for printing out array values) and for setting breakpoints.
Booklaylet is a JS library for letting you easily deploy your bookmarklet52 applications. The implementation is dead simple: take the Booklaylet source and modify it to point to your app's URL.
JavaScipTools is a collection of useful JS components, functions, and classes with the aim of addressing some of the more common web developer tasks such as parsing and formatting of data types (i.e. date and time). It also comes with a dynamic table function for creating sortable HTML tables.
HTML 5's Canvas element gives developers a way to draw stuff on web pages programmatically. Doodle.js is a utility library/framework for working with more complex and robust Canvas drawing processes. Check out Spiral Pattern54 demo and the Marbles in Space55 (3D simulation) demo in a browser that already supports Canvas to get a feel for how Doodle.js works.
liteAJaX is a lightweight JavaScript class for working with AJAX. This library is perfect for projects that don't use a JavaScript/Ajax framework or projects that don't need a more robust and fully-featured framework.
Burst is a vector animation engine for HTML 5's Canvas element. With it, you can create smooth, Flash-like animation effects for browsers that support Canvas.
JSTestDriver is a Java-based framework for creating unit test following Test-Driven Development58 philosophies and best practices. Be sure to check out this video demonstration of JSTestDriver in action59.
This library allows you to create PDF's using nothing else but JavaScript. See the jsPDF demo page to see the library in action.
Useful JavaScript Libraries Link
GlassBox is a beautiful and refreshing take on modal windows that creates an interesting feeling of transparency as if you were looking through a glass. Check out the example page62 to see different types of GlassBox implementations.
jQuery TOOLS64
jQuery TOOLS is a toolbox that gives developers some of the most popular UI design patterns at their disposal in an easy-to-use manner. View some of the things you can do with jQuery TOOLS in the project's demo page.
Moosture is a JavaScript library for dealing with mouse gestures, written on top of the MooTools framework.
Tablecloth is a lightweight and unobtrusive JavaScript library for styling and adding dynamic user interaction to HTML tables.
Unobtrusive Table Actions Script
This simple and lightweight library brings together a set of common and useful functions for dealing with HTML tables, such as zebra-striping rows, highlighting rows on mouse over, and column highlighting.
LivePipe is a set of widgets and controls for adding common user interaction components to web applications using the Prototype JavaScript framework.
JavaScript Graphical / Virtual Keyboard Interface
This JavaScript package adds a virtual keyboard interface into web pages.
Tipmage is a JavaScript class for handling tooltips and annotations on images, similar to annotated images on Flickr.
qGallery is a simple but beautiful JavaScript for creating image galleries with smooth and slick animation effects.
Educational JavaScript Resources and Tutorials Link
Ajax Frameworks Decision Center
For large companies, committing to a JavaScript/Ajax framework such as Prototype, MooTools, or jQuery is a big decision because it affects a large amount of employees and will dictate the direction of the company's client-side interaction and RIA development philosophies. Using the Ajax Frameworks Decision Center gives you an organized, quantitative, and thorough method for making a solid decision.
jQuery vs MooTools75
This single-page site by MooTools Dev Team member Aaron Newton is a comparative look into jQuery versus MooTools.
Ajax Framework Analysis Results76
This analysis of popular JavaScript/Ajax frameworks (Dojo, Ext JS, GWT, YUI) is a great resource for gathering research data for your own frameworks: the analysis matrix factors in criteria such as scalability, extensibility, quality and quantity of documentation, and much more. You can adapt this matrix, tweak their weights, and modify criterions to help you decide which JS framework to go with.
Sexy Drop Down Menu w/ jQuery & CSS78
In this tutorial, you'll learn how to create a multi-tiered drop down menu with the use of the jQuery library.
Easy Display Switch with CSS and jQuery80
This tutorial outlines a method for using jQuery to smoothly-transition into different viewing modes, which can be helpful in image galleries.
Create a Slick and Accessible Slideshow Using jQuery82
This is a step-by-step jQuery tutorial that I wrote for creating a simple and slick slideshow that can be adapted to display different content types. Check out the demo page83 to see the slideshow in action.
Learning Advanced JavaScript85
John Resig has a slideshow-style, web-based tutorial on advanced JavaScript development. It is a wonderful stepping-stone for JavaScript developers ready to make the leap into RIA development using JavaScript.
JavaScript tests & Compatibility tables87
Code Conventions for the JavaScript89
On this page, you can find suggested coding conventions for JavaScript. It is important to note that there is no one correct convention, but this is a great place to start developing your own.
Footnotes Link
- 1 /2009/02/08/50-extremely-useful-javascript-tools/
- 2 /2009/03/02/40-stand-alone-javascript-libraries-for-specific-purposes/
- 3 /2008/09/16/jquery-examples-and-best-practices/
- 4 http://ejohn.org/blog/fireunit/
- 5 http://www.softwareishard.com/blog/firebug/fireunit-testing-in-the-firebug-world/
- 6 http://ejohn.org/blog/fireunit/
- 7 http://sugartest.scriptia.net/
- 8 http://sugartest.scriptia.net/
- 9 http://jsclass.jcoglan.com/
- 10 http://jsclass.jcoglan.com/
- 11 http://jsonformatter.curiousconcept.com/
- 12 http://icant.co.uk/sandbox/fauxconsole/
- 13 http://jsbin.com/
- 14 http://jsbin.com/about#video
- 15 http://jsbin.com/
- 16 http://phpjs.org/
- 17 http://code.google.com/speed/page-speed/
- 18 http://developer.yahoo.com/yslow/
- 19 http://stevesouders.com/
- 20 http://code.google.com/speed/page-speed/
- 21 http://james.padolsey.com/javascript/prettyprint-for-javascript/
- 22 http://www.petefreitag.com/images/blog/jsdump.gif
- 23 http://james.padolsey.com/javascript/prettyprint-for-javascript/
- 24 http://www.spket.com/
- 25 http://www.spket.com/javascript-formatter.html
- 26 http://www.spket.com/
- 27 http://robertnyman.com/obtrusive-javascript-checker/
- 28 https://addons.mozilla.org/en-US/firefox/addon/9505
- 29 http://code.google.com/p/obtrusivejavascriptchecker/downloads/detail?name=ObtrusiveJavaScriptChecker-0.8.user.js&can=2
- 30 http://softwaremaniacs.org/soft/highlight/en/
- 31 http://softwaremaniacs.org/soft/highlight/en/
- 32 http://javascriptcompressor.com/
- 33 http://javascriptcompressor.com/
- 34 http://www.incaseofstairs.com/firediff/
- 35 http://www.incaseofstairs.com/firediff/
- 36 http://rockstarapps.com/joomla-1.5.8/products/razor-web-profiler/overview.html
- 37 http://userjs.up.seesaa.net/js/bookmarklet.html
- 38 http://userjs.up.seesaa.net/js/bookmarklet.html
- 39 http://www.jscharts.com/home
- 40 http://code.google.com/p/jsspec/downloads/list
- 41 http://iphoneized.com/2009/04/basejs-mobile-safari-javascript-framework/
- 42 http://mochaui.com/
- 43 http://mochaui.com/demo/
- 44 http://mochaui.com/
- 45 https://wiki.mozilla.org/ServerJS
- 46 http://pear.php.net/
- 47 http://www.uploadify.com/
- 48 http://www.uploadify.com/demo/
- 49 http://www.gscottolson.com/blackbirdjs/
- 50 http://www.gscottolson.com/blackbirdjs/
- 51 http://www.digitalhymn.com/argilla/booklaylet/
- 52 http://en.wikipedia.org/wiki/Bookmarklet
- 53 http://javascriptools.sourceforge.net/
- 54 #
- 55 #
- 56 http://digitalhymn.com/argilla/liteajax/
- 57 http://code.google.com/p/js-test-driver/
- 58 http://en.wikipedia.org/wiki/Test-driven_development
- 59 http://www.youtube.com/watch?v=V4wYrR6t5gE&eurl=http%3A%2F%2Fwww%2Egmodules%2Ecom%2Fgadgets%2Fifr%3Furl%3Dhttp%253A%252F%252Fgoogle%2Dcode%2Dproject%2Dhosting%2Dgadgets%2Egooglecode%2Ecom%252Fsvn%252Fbuild%252Fprod%252Fv&feature=player_embedded
- 60 http://code.google.com/p/jspdf/
- 61 http://www.glassbox-js.com/
- 62 http://www.glassbox-js.com/#examples
- 63 http://www.glassbox-js.com/
- 64
- 65
- 66 http://neofreeman.freepgs.com/Moousture/
- 67 http://cssglobe.com/lab/tablecloth/
- 68 http://cssglobe.com/lab/tablecloth/
- 69 http://livepipe.net/
- 70 http://livepipe.net/
- 71 http://digitalhymn.com/argilla/tipmage/
- 72 http://digitalhymn.com/argilla/tipmage/
- 73 http://qgallery.quadrifolia.de/
- 74 http://qgallery.quadrifolia.de/
- 75 http://jqueryvsmootools.com/
- 76 http://raibledesigns.com/rd/entry/ajax_framework_analysis_results
- 77 http://raibledesigns.com/rd/entry/ajax_framework_analysis_results
- 78 http://www.noupe.com/tutorial/drop-down-menu-jquery-css.html
- 79 http://www.noupe.com/tutorial/drop-down-menu-jquery-css.html
- 80 http://designm.ag/tutorials/jquery-display-switch/
- 81 http://designm.ag/tutorials/jquery-display-switch/
- 82 http://sixrevisions.com/tutorials/javascript_tutorial/create-a-slick-and-accessible-slideshow-using-jquery/
- 83 http://sixrevisions.com/demo/slideshow/final.html
- 84 http://sixrevisions.com/tutorials/javascript_tutorial/create-a-slick-and-accessible-slideshow-using-jquery/
- 85 http://ejohn.org/apps/learn/
- 86 http://ejohn.org/apps/learn/
- 87 http://robertnyman.com/javascript/
- 88 http://robertnyman.com/javascript/
- 89 http://javascript.crockford.com/code.html
Hold on, Tiger! Thank you for reading the article. Did you know that we also publish printed books and run friendly conferences – crafted for pros like you? Like SmashingConf Barcelona, on October 25–26, with smart design patterns and front-end techniques.
↑ Back to top Tweet itShare on Facebook


text:
Millipore Corporation (MIL) Q3 2009 Earnings Call Transcript November 5, 2009 4:45 PM ET
Joshua Young – Director, IR
Martin Madaus – Chairman, President and CEO
Charlie Wagner – Corporate VP and CFO
Derik DeBruin – UBS
Tycho Peterson – JPMorgan
Isaac Ro – Leerink Swann
Marshall Urist – Morgan Stanley
Jon Groberg – Macquarie Capital
Dan Leonard – First Analysis
Eric [ph] – Thomas Weisel Partners
Good afternoon. My name is Casey and I will your conference operator today. At this time, I would like to welcome everyone to the Millipore's third quarter 2009 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator instructions) Thank you. Mr. Young, you may begin your conference.
Joshua Young
Thank you very much, Casey. Good evening. I would like to welcome everyone to Millipore's third quarter 2009 earnings conference call. My name is Joshua Young and I am the Director of Investor Relations for Millipore. And joining me on today's call are Martin Madaus, Chairman, President and CEO; and Charlie Wagner, Chief Financial Officer.
In addition to the earnings release we issued earlier today, we will be referencing a slide presentation as part of today's call. This presentation can be viewed by clicking on the webcast link on the millipore.com homepage or by accessing Millipore's Investor Relations website. A PDF copy of the slides will be posted to our website after the call. We will also be highlighting non-GAAP information. A reconciliation of our GAAP financials to our non-GAAP financial measures is included in our earnings release and posted on our website.
Before we begin, I will make the usual Safe Harbor statement that during the course of this conference call, we will be making forward-looking statements regarding future events or the financial performance of the company that involve risks and uncertainties. The company's actual results may differ materially from the projections described in such statements. Factors that might cause such differences include but are not limited to those discussed in today's earnings release and in our Form 10-K, as well as other subsequent SEC filings.
Also note that the following information is related to current business conditions and our outlook as of today, November 5, 2009. Consistent with our prior practice, we do not intend to update our projections based on new information, future events or other reasons prior to the release of our fourth quarter financial results.
Now I would like to turn the call over to Martin Madaus.
Martin Madaus
Thanks, Joshua. Good evening, everybody. Thank you for joining us on the call today. Q3 was another very strong quarter of operational performance for Millipore. Many of the same trends that began early in the year continued in the third quarter. There are parts of our business that are performing extremely well, while there are few other areas that remained somewhat soft, but overall driving very strong growth in revenues and earnings and in cash flow.
The key contributors for this quarter's great results are the following. First, our Bioprocess Division is sustaining its strong momentum and is generating very attractive growth. Just as we projected last year, the division's performance has returned to tracking the strong fundamentals of the biotech industry and that we have seen also an additional benefit of an increase in vaccine productions.
Second, we saw an improvement in our Bioscience Division performance, but segment of the bioscience market remained soft. It's right now a difficult environment to sell laboratory instrumentation and spending from large pharmaceutical customers remains weak. The good news is that we continue to grow faster than many of our peers, but the division is still well below the levels of growth we've seen over the past five years.
Third, we are capitalizing on the strength of our business to invest in our future growth. We continue to increase our R&D spending in the third quarter and we are improving our innovation capabilities throughout the company. Our higher growth and profitability gives us the opportunity now to invest while the general market is in a downturn. This investment will benefit our competitive position over time.
Finally, our cash flow performance continued to be outstanding. We generated approximately $112 million in free cash flow in the third quarter. And in the first nine months, we have generated $234 million of free cash flow already surpassing the cash flow that we generated all of last year. This exceptional performance is primarily the result of a substantial improvement in our working capital efficiency.
The programs we launched to improve our cash flow have been a resounding success, and we continued to use our cash to pay down our debt, which is increasing our flexibility to make strategic growth investments in the business.
So with that brief summary, let me move into some more specific comments about Q3. Third quarter revenue increased 4% to $412 million. If you exclude a 3% unfavorable effect from changes in foreign currency exchange rates, organic revenue growth in the quarter was 7%. From a divisional perspective, if you exclude the effects of changes in foreign exchange rates, the Bioprocess grew 8% organically while the Bioscience Division generated 4% organic growth.
On the bottom line, we reported $0.95 in non-GAAP earnings per share, which is about $0.02 higher than last year. We took advantage of the high levels of profitability we generated through the first six months of '09 to make investments in our business during the second half of the year. This higher level of spending combined with a higher year-over-year tax rate lowered our earnings growth in Q3.
Year-to-date, our non-GAAP earnings per share growing at 13%, and we are in a position to generate attractive earnings growth for the full year. Finally, our free cash flow grew at a rapid rate of 74% compared to the third quarter of 2008.
So I'm quite pleased with all these results as we are on track to meet and exceed all of our financial targets in 2009 despite the general turmoil in the market and challenges. So let's view now each of our two divisions in a bit more detail. I'll start with the Bioprocess Division.
The Bioprocess Division started off being strong and its performance has remained strong throughout 2009. During Q3, we grew organically in all geographies and we saw strength across a number of different product lines. Bioprocess continues to benefit from the favorable trends we saw earlier this year. Our growth has still been driven by very good spending from our large biotech customers.
The biotech business is up in double digits in revenues, as many customers are increasing production to meet their solid underlying demand in the market. For this year, sales of our consumable products have more closely aligned with our customers manufacturing campaigns and what we experienced in 2008.
There are two other drivers of our biotech business worth noting. First, our vaccine business is up nicely on a year-over-year basis due to the increasing sales to manufacturers who ramp up production for the H1N1 flu virus. There are approximately 20 companies who worked to [ph] manufacture the vaccine worldwide. And many of these are our largest customers.
And as many of you know, our products are used widely through vaccine manufacturing process from separation to purifying the antigen, which is the key component of manufacturing that vaccine to quality control testing of the final vaccine before it is released into the market. So as a result, demand for sterile filtration, tangential flow filtration, disposable manufacturing and sterility testing have all seen a nice uptick in sales.
Many of these customers who are producing vaccine began to accelerate their production in July. So we saw the greater revenue impact in our vaccine business during Q3. And since many of these manufacturers are located in Europe, this has created the biggest positive benefit in Europe. We are not specifically breaking our revenues from a specific segment like vaccine production, but I can tell you that's an important driver – it was an important driver in Q3 for our performance and will also be meaningful in Q4.
When you look forward, there is uncertainty about the future production levels of this specific vaccine for H1N1. So our best estimate at this time is that we would expect the H1N1 strain to be just included in the standard, seasonal flu vaccine in the future rather than having two separate vaccines that are manufactured this year. So, resulting from that is that it's unlikely that we will have the same level of H1N1 vaccine production in 2010. There will be some.
Second important revenue trend, our biotech business comes from the strong growth we've seen in Singapore and China. We believe that much of the increased volume in the region is really incremental production to meet expanded market growth. Customers in these markets are expanding capacity and we are beginning to see some of the first plants come on line in the region. And in response to this expansion, we've also made a number of investments to support the rapid growth.
Our Bioprocess team just concluded a very successful tour of several countries, presenting best practice approach for biotech manufacturing, and there were standing-room-only crowds in each of the cities. I expect that Bioprocess growth in Singapore and in China, some other countries will continue to be very important part of our performance as we enter into 2010.
And interesting in multiple strength of the division was also what we called a classic pharma business, which is a little less than half the Bioprocess business. And while this business has been historically a little bit more sensitive and lower growing, it had shown great strength in the last quarter. And certain segments in that business, such as plasma market, are up 20%, which again contributes to our overall performance.
Now let's talk about products for a little bit. Our downstream bioprocess business unit led the growth for the third quarter in a row. Here the products are chromatography, tangential flow filtration, clarification and biofiltration. All of these product lines, core product lines, performed very well. We also had very high growth of our disposable manufacturing product lines and we booked some new first orders for the revolutionary Mobius FlexReady systems.
We had also very good growth in disposable tubing and connector products, all performed well. And again, these products are in part also used by vaccine manufacturers to do final finish and fill. Process monitoring products are also very steady in the quarter, grew well, driven by onsite testing and disposable sampling that came from our NovAseptic acquisition. And this is in response to increased production levels.
So, to sum up the Q3 performance in Bioprocess Division, continued to deliver strong performance, is on track to have really an excellent year. With the first nine months of 2009, we've generated 9% organic revenue growth, which is exceptional performance in the current environment. And this performance just reinforces my view, and our business is less affected by downturns in the economic cycle.
If we look forward, we see the same trends as we have in Q3. Large biotech accounts increase the spending, higher levels of vaccine production and good continued growth in China, Singapore that should continue through the fourth quarter. I think I commented last year that I couldn't wait for the day when I could once again say that the division is back on track, and now I can certainly say that they have come.
Now let's turn to the Bioscience Division. We generated 4% organic revenue growth in the division during Q3 and have grown the business 3% organically through the first nine months of the year, which I will call solid growth in a challenging business environment. Our organic growth in Q3 is a nice increase from the flat performance we saw in Q2. So we are clearly seeing modest levels of improvement. As a result, I would characterize Bioscience business performance right now as stabilizing.
The market isn't much better, but it's also not worse. The trends and customer buying patterns are very comparable to what we saw when we last spoke in August. On the positive side, we are growing faster than the market and faster than many of our peers. We have a very good consumable product portfolio, and that continues to be resilient and is growing nicely, particularly in the academic accounts where we are seeing overall activity.
We also are seeing modestly better performance in Asia. So for example, the Bioscience business in Japan was seeing really steep declines early in the year and that has clearly stabilized, and also that's an improvement trend. But overall, Bioscience business is still tracking well below its long-term growth rate for two main reasons. First, we continued to see weakness at larger pharma companies. Pharmaceutical customers are rationalizing network pipelines, recessing their research priorities, and they focus very much on integrating acquisitions.
Second, it's a more difficult environment to sell lab instrumentation. We see a continuation of the trend we had in Q2. But even though these are some challenges, we still are able to grow (inaudible) based business. Geographically, Bioscience Division generated year-over-year organic growth in all geographies. Additionally, each geographic region reported high organic growth rates than what we experienced in Q2 2009.
Products, our life science business unit continued to be the best performer in the Bioscience portfolio. The market for life science research consumables remained steady. And as I mentioned earlier, our academic customers remain healthy and continue to drive very good levels of research activity. The life science business unit in Bioscience is really the primary beneficiary of the strength since it has really the most exposure to that market.
The business unit grew faster than the overall division, as consumable products in really hard research areas such as neuroscience, stem cell research, metabolic research continue to be strong. And this strength has helped particularly our multiplex immunoassay kits, which is still one of the fastest growing product lines in the Millipore portfolio.
Also, our most recent acquisition, our flow cytometry instrumentation and reagents continue to drive attractive growth and have a strong uptick by the academic accounts, and that in turn helps offset somewhat weaker sales of these products into pharmaceutical customers. We also have some success with our diagnostic test kits that detect a flu and that has also resulted in becoming a nice addition to our growth.
We have – many of you received questions about the impact of the US federal stimulus package on our business. So we speak to that. We have seen a lot of grant writing activity, particularly related to Guava flow cytometry instruments. But we have not seen a major impact, a major noticeable impact from the stimulus package.
We are a consumables driven company and we will not see the impact from additional spending until the grant money is actually released and researchers are actually in the labs conducting experiments. So we don't expect this to happen until the second half of 2010, and the impact on our business will likely be modest since about 70% of the Bioscience Division revenues are generated outside of the US.
Moving on to lab water, our lab water business continued to grow in Q3, delivering similar performance to what we experienced in the last quarter. We generated solid sales growth in services and consumables, which was offset by flat performance in lab water instrumentation and accessories. We expect to generate low-single digit growth in lab water during 2009, and (inaudible) the business will ultimately benefit as we see a cover in capital spending and an improved environment for selling laboratory instrumentation.
In the meantime, with 60% of the business derived from consumer growth and services, we continue to grow the business performing better than most of our instrumentation-driven businesses – most other instrumentation-driven businesses.
Moving on drug discovery, our smallest business unit, this business and service business continues to be adversely affected by cancellation and delays of services, contracts that we have with large pharmaceutical customers. These contracts are mainly focused on small molecules of discovery services and almost all business is coming from the pharmaceutical industry.
And as I mentioned earlier, continued cutbacks by these customers, most pronounced and bright spot in drug discovery continues to be our rapid growth in the biopharmaceutical service business. So this is one marked difference as an increased number of biologics enter the pipeline. Companies are leveraging our immunoassay multiplex expertise to help them to develop drugs and bring them to market a little bit faster.
During the quarter, we completed the acquisition of BioAnaLab that's a UK-based company that provides a broad range of services to assist companies with value-added advancing protein-based drugs. Strategically, this transaction will help us to expand our offering in Europe and to better serve our multinational customer base. To me, this bolt-on acquisition is a great example how we are executing our acquisition strategy and expanding to really rapidly growing markets and leverage our global brand presence.
So to sum up our Bioscience performance in Q3, the division is proving to be resilient and generating above market growth in a difficult market environment. Pharma spending remains sluggish and it's difficult to sell out instrumentation right now. But the division's performance improved modestly from the last quarter and is growing faster than most peers in 2009.
Before I turn it over to Charlie who will go through the financials in more detail, I want to leave you with some thoughts about 2009. 2009 will not only be a year of very attractive financial performance from Millipore, but it's also a year marked by targeted investments that will help us to underpin the organic revenue growth in the future.
Clearly, one of the advantages of growing at a time when many of our competitors are seeing declining revenues is that we have greater flexibility to make investments to drive future growth. This higher level of investment is reflected in the growth of R&D spending this quarter, which was up 15% over last year. Innovation that at the heart of our company is critical to the long-term success of Millipore. Our customers are driven by innovation and so are we.
Our ability to anticipate customer needs and deliver high value differentiated product, the single most important factor in creating long-term value for customers and shareholders. We are investing in innovation, the combination of internal R&D, third-party collaborations and acquisitions. We are focusing on internal investments on programs that will expand our presence in very dynamic market segments such as disposable and manufacturing, rapid testing in real-time process monitoring, stem cell research, virus filtration and flow cytometry and many more in the future.
Our approach is to leverage both our own capabilities and technologies and capabilities provided by the partners, third-party companies to develop what we call differentiated solutions. Our pipeline of promising R&D projects is the strongest I've seen in my five years at Millipore. It has grown broader and more innovative every year.
We are leading in many fields, and because we have scientists and marketing experts that understand how customers work, we can apply this knowledge into products and services solutions like very few companies can. And that is the promise of the Millipore brand. That's what we call advancing life science together with our customers.
So with that, I'll turn it over to Charlie.
Charlie Wagner
Thanks, Martin. I'll now provide some additional details on Q3 and year-to-date results and our full year 2009 outlook. I'll begin with a discussion of our GAAP operating results in the third quarter. Total revenues increased 4% from last year's third quarter. Excluding a 3% unfavorable impact from changes in foreign exchange rates, organic revenue growth was 7% in the quarter. Revenues from our BioAnaLab acquisition were not material in the quarter, and Guava-related revenues are now part of our organic growth since we had Guava-related revenues in Q3 of 2008.
Our gross profit margin increased 130 basis points on a year-over-year basis from an expense standpoint. SG&A costs increased 6% on a year-over-year basis, while our R&D spending was up 15%. Our GAAP operating margin increased slightly to 15.3% from 15.1% in Q3 2009, and earnings per share were $0.71 compared to $0.68 in Q3 2008.
From a geographic perspective and excluding the effects of foreign currency translation, our revenue growth was 6% in both the Americas and Europe while our business in Asia grew 10%. Both of our divisions saw improved performance in Europe during the quarter, with our Bioprocess Division benefiting from higher levels of vaccine production in the region. Our growth in Asia continues to be driven by China and Singapore.
We are seeing good growth from both divisions in China, while our growth in Singapore is more specific to our Bioprocess Division and expanded biotech manufacturing in the region. Asia also benefited from better performance in Japan, particularly in our Bioscience business where we had seen double-digit declines earlier in the year.
On the next slide, we show our Q3 2009 non-GAAP operating results. And as always, I encourage you to review the non-GAAP reconciliation table in the press release for the detail of our adjustments. Last quarter I talked about how we expected to leverage our strong first half profitability to invest in our business during the second half of the year. Our Q3 non-GAAP performance reflects higher levels of spending than our original plan for the year, particularly in R&D.
Our Q3 2009 non-GAAP gross margin of 55.3% was an increase of 30 basis points on a year-over-year comparison due to a positive impact from changes in foreign currency and higher pricing. These benefits were somewhat offset by a negative product mix and higher incentive compensation costs. And despite higher sales volumes, manufacturing levels were roughly the same as last year, as we decreased inventory during the period.
From a mix perspective, the negative product mix was primarily related to our Bioprocess Division, as the higher percentage of our downstream processing revenues came from lower margin products such as chromatography, media and systems hardware. We also saw lower year-over-year revenues from some of our high margin upstream bioprocessing products.
Non-GAAP SG&A expenses represented 28.8% of sales compared to 28.6% in Q3 2008, an increase of 20 basis points. Increases in incentive compensation costs were offset by the favorable effects of foreign currency translation. R&D spending as a percent of revenue increased 70 basis points from the third quarter of last year, representing 7.1% of sales.
Last quarter I told you that our R&D spending would be up by at least $8 million in the second half of 2009 compared to the second half of 2008. We are on pace to meet that level of investment with non-GAAP R&D costs up approximately $4 million or 16% on a year-over-year basis.
We made a number of investments to advance our innovation strategy in both divisions. The increase reflects higher headcount, incentive compensation, project related spending, and payments to third-party technology partners. Non-GAAP operating margin in Q3 was 19.5%, a decrease of 60 basis points from the previous year, reflecting the higher level of investment in the business.
Our non-GAAP tax rate in Q3 was 22.8%, a 330 basis point increase from the previous year due to a higher proportion pretax income coming from higher tax jurisdictions. On a sequential basis, our Q3 tax rate was lower due primarily to the reversal of tax reserves when the statute of limitations expired during the quarter.
Our net interest expense was $11 million, approximately $3 million lower than last year, due primarily to lower debt balances. And we've kept our promise to substantially reduce our debt balances over the last several years. At the end of Q3, we have effectively paid off our primary revolving credit facility and we had $776 million of net debt.
We reported $0.95 in non-GAAP EPS, which was $0.02 higher than Q3 2008. Changes in foreign exchange rate added approximately $0.08 in EPS compared to the third quarter of 2008.
Moving on to the GAAP results for the first nine months of the year, total revenues increased 2% compared to the first nine months of 2008. Excluding a 6% unfavorable impact from changes in foreign exchange rates and a 1% contribution from the Guava acquisition, revenues grew 7% organically through the first nine months of the year.
Our GAAP operating margin increased to 16.6% from 15.5%, and our earnings per share in the first nine months of 2009 were $2.38 compared to $1.91 in the first nine months of 2008, growth of 24%. Our GAAP pretax income in the first nine months of 2009 benefited from a $9 million gain on our acquisition of Guava Technologies and a $10 million year-over-year decrease in net interest expense due to lower debt balances and slightly improved interest rates.
On the next slide, I show our performance by geography for the first nine months of the year. Excluding changes in foreign exchange rates, we have grown revenues in the Americas by 10% due to the strong performance of our Bioprocess Division. In Europe, we have grown the business 5% and it's well balanced between the two divisions. And finally, revenues in Asia have grown by 6%, which is a bit lower than we would like in the region, but it reflects the weak performance of Japan in the first part of this year.
On the next slide, we show our nine-month non-GAAP operating results. Again I'd encourage you review the non-GAAP reconciliation table in the press release for the detail of the adjustments. Through the first nine months of the year, we are generating attractive margin expansion. This expansion came from some of the operational improvements and the positive impact of changes in foreign exchange rates, which were offset by higher levels of investment in the business.
Our non-GAAP gross margin of the first nine months of 2009 of 56.5% was an increase of 140 basis points due to a positive foreign currency rate impact, pricing increases and operational improvements. These effects were offset by a negative product mix, higher incentive compensation costs, and lower manufacturing volumes and inventory write-downs that were partially the result of our working capital initiatives.
SG&A expenses represented 28.5% of sales compared to 28.7% in the first nine months of 2008, a decrease of 20 basis points. The effect of higher incentive compensation expenses was offset by the favorable effects of foreign currency translation. R&D spending increased 50 basis points to 6.8% of sales from the first nine months of 2008.
Non-GAAP operating margin of 21.2% for the first nine months of 2009 was 110 basis point improvement from the previous year. We are on track to have a very strong year of margin expansion and we are showing strong leverage in the business. Our non-GAAP tax rate for the first nine months was approximately 25%. Our non-GAAP net interest expense was $32 million, which is approximately $11 million lower than last year due to lower debt balances and improved rates.
For the first nine months of 2009, we reported $3 in non-GAAP EPS, an increase of 13% over the first nine months of 2008. Changes in foreign exchange rates had no impact on our earnings per share on a year-to-date basis.
Now turning to our balance sheet, we reduced net working capital by over $50 million in the third quarter and improved all three drivers of our cash conversion cycle. Compared with last year's third quarter, we achieved a five-day improvement in days sales outstanding to 66 days and 8-day improvement in inventory days to 130, and a 3-day improvement in days payable outstanding to 41 days. Our improvement in DSO was the result of process improvements and customer collections and better enforcement of customer payment terms.
Turning to inventory, we improved the way we manage our inventory by executing programs to reduce our lead-times and cycle times and shrink our manufacturing lot sizes and safety stock. Importantly, we've done this while improving our on-time customer shipment rate at the same time. We are also rationalizing select products as part of our efforts to improve our product life cycle management.
Finally, our cash flow benefited from negotiating better terms with our suppliers and from the timing of certain payments. Overall, the net result of these improvements is that we have improved our cash conversion cycle by 16 days compared to the third quarter of 2008 and by 10 days compared to the second quarter of 2009.
Continuing down the cash flow statement. Cash flow from operations during Q3 was $130 million. Factoring in CapEx spending of $18 million, we generated $112 million of free cash flow in the quarter. Our cash flow performance reflected a significant contribution from working capital reductions, primarily as a result of implementing our working capital program.
Through the first nine months of 2009, cash flow from operations totaled $287 million. We've incurred $53 million in CapEx, resulting in $234 million of free cash flow for the first nine months of the year. The key drivers of the year-to-date cash flow performance are strong profitability and the working capital improvements I mentioned earlier.
When I began my tenure as CFO in August 2007, I shared with you that improving our cash flow performance was one of my highest priorities. And I'm pleased to report that the initiatives we've put in place are driving tremendous value and results for the company. We are on pace to generate record level of free cash flow for the company in 2009. In addition to substantial improvement in our balance sheet metrics, we have also significantly lowered the company's CapEx spending as a percentage of our sales.
I show on this slide how substantially our free cash flow generation has improved as a result of the program from our working capital initiative. We have used most of this cash flow to pay down our primary revolving credit facility, which now has only $14 million balance as of the end of the quarter. While we have improved tremendously, we still have more room to improve in the future, especially as we target reducing our inventory days of supply to below 120 days.
Now let me turn to our guidance for the remainder of the year. We are reiterating our revenue and earnings guidance for 2009. We expect that we will report full year 2009 revenue growth between 2% and 3%, excluding a 3% unfavorable impact from changes in foreign currency, we expect to generate between 5% and 6% revenue growth, which includes one percentage point of growth from acquisitions.
We expect to generate non-GAAP earnings per share of approximately $3.85 to $3.95 per share. This EPS estimate is based on a projected non-GAAP tax rate for the full year of 25% to 26%. We expect that our fourth quarter tax rate will be as much as 10 percentage points higher than the fourth quarter of 2008, as several discrete items that affected Q4 2008 will not repeat this year.
This earnings guidance also assumes the changes in foreign exchange rates, will add about $0.07 to earnings per share for the full year. I mentioned on previous calls that the anomaly of our fiscal calendar will impact the comparability of our financial results during some of the quarters of 2009. During Q1, we benefited from having ForEx for selling days. In the fourth quarter, we will have five fewer selling days, resulting in one last selling day for the full year. I mention this to you again since you need to take these dynamics into account when making year-over-year or sequential comparisons of the company's performance.
Now turning to cash flow guidance, we are increasing our guidance for free cash flow in 2009 and expect free cash flow to total approximately $265 million. As a reminder, we define free cash flow as cash flow from operations less capital expenditures.
So to summarize, the key takeaways from the third quarter we delivered another strong quarter of financial results, we are making important investments for future growth, and we are generating record levels of free cash flow.
With that, let me turn it over to Joshua.
Joshua Young
Thank you. Casey, if you could please assemble the Q&A roster.
Question-and-Answer Session
Yes, sir. (Operator instructions) And our first question will come from Derik DeBruin.
Derik DeBruin – UBS
Hi, good afternoon.
Martin Madaus
Good afternoon.
Charlie Wagner
Hi, Derik.
Derik DeBruin – UBS
Hi. So, just looking at the – Charlie, looking at the gross margin for the quarter, I mean, you cited a bunch of reasons why it was down. I guess how do we look at the gross margin number for the fourth quarter, same type of mix issues (inaudible) impacting there? And I guess what do you see when you look to next year just given all the current fluctuations and just do you still expect to see gross margin expansion in 2010?
Charlie Wagner
So Derik, you're focused on sequential Q2 versus Q3?
Derik DeBruin – UBS
Actually sequential Q3 and just kind of what you think about in Q4 if you're going to expect to see the same type of mix issues in Q4.
Charlie Wagner
Yes. Gross margin, obviously, it's the mosaic of driver. So, you really have to focus on the few things to understand what happened there. Certainly mix had an impact in the quarter. And also as I mentioned, we took inventory levels down and also had some inventory write-offs associated with product rationalization. So those are some of the dynamics of the current quarter. Some of that does continue into the fourth quarter as well. I think the best way to think about it is that I've said I think a few times it's very hard to look at gross margin in an individual quarter and draw too many conclusions because of the way the cost flow through the P&L – So if you at the year-to-date, the improvement of $140 basis points, good chuck of that is from currency, some of it is from operating improvements, and we would look at our ability to improve margins on a constant currency basis. That should continue into 2010 as well.
Derik DeBruin – UBS
Okay. I guess let's say, just looking at the historicals, I mean, typically Q4 tends to be sequentially down from Q3. And I just was wondering if that's the same trend that's going to repeat this year? That's where I was going to go with that.
Charlie Wagner
Got it.
Derik DeBruin – UBS
Okay. And I guess how – what are you expecting for the top line impact on FX in Q4, and what are your first takes on looking at 2010 for the FX impact?
Charlie Wagner
No point of view on 2010 yet, Derik. And Q4, I don't have that handy. We can do that offline.
Derik DeBruin – UBS
No problem. And I guess, Martin, you noted some expansion in Asia in the Bioprocess business. I guess what products are they making?
Martin Madaus
Well, it's across the board. Our core filtration products will be required more because it's not only the expansion of volume, it's also the increase and quality requirements that is happening, particularly in China and then we have a very strong growth in our monoclonal production in Singapore with the large multinational organization. And our investment is around adding – technical people can support customer and we're opening another lab in Singapore. It's a very strong trend and it will continue. So it's a good fundamental trend.
Derik DeBruin – UBS
Great. And then just one final question, Charlie you said you had $155 million in debt in the quarter?
Charlie Wagner
That's right.
Derik DeBruin – UBS
Okay. And what's the interest rate on that?
Charlie Wagner
It's all fixed rates. It's in the neighborhood of five basically.
Derik DeBruin – UBS
Great. That's what I thought. Thank you very much.
Our next question will come from Tycho Peterson with JPMorgan.
Tycho Peterson – JPMorgan
Hey, good afternoon.
Martin Madaus
Good afternoon.
Tycho Peterson – JPMorgan
Maybe just going off Derik's question earlier about Asia, can you talk a little bit about from an infrastructure perspective how you feel? And you talked a lot about stepping up R&D investments. Can you talk a little bit about sales and where you may need to add and how we should think about that trending?
Martin Madaus
We have – the countries in Asia that are most relevant to our business are Singapore right now and China and Japan basically because our largest Asian business recovering. But in terms of investments, we are adding sales and technical people, particularly in China. We've done that in Singapore during the end of last year and early this year. And infrastructure are – mainly investments into more laboratory capabilities that help customers to do certain validation procedures and scale-up capabilities. So it's a mixture of training people, adding new technical people and transferring some of our knowledge down there.
Tycho Peterson – JPMorgan
Okay. That's helpful. And in terms of some of the product launches, you talked I think in your comments about Mobius Flex, can you talk a little bit about the early demand and maybe give us some sense as to how large do you think that opportunity might be? I guess you will have five modules out by early next year?
Charlie Wagner
We have four out to date, and the launch is good so far. The selling cycle in biotech is long gone, but it's a first generation of products that will be followed up by many other versions. Our vision is to basically simplify the entire downstream production process. And this is the first series of a number of products. The feedback is very good. We see it in a number of trials that we see with these products. And as I said, we have received a number of orders already. And so we have booked some sales, which is pretty good after a few months in this industry. So that's a key product. I should also say that our more classical products, very strong, particularly when you talk about the virus filtration products, is contributing a lot to our new product growth, our clarification products. And we have seen also some new wins in chromatography, which we have worked on for long time. So we are also getting some additional customers in chromatography.
Tycho Peterson – JPMorgan
Okay. And then just one last one on drug discovery, you talked about some of the challenges with the pharma M&A. Is your sense that that is better next year or how disruptive do you think –?
Charlie Wagner
Well, I sure hope it is better next year. Pharma companies are in the business of discovering drugs, and they will come back at one point. What's difficult to call is when this will happen. So at this point, we have experienced a lot of cancellations this year. But at the same time, we are also seeing a lot of interests. So there is a lot of quoting going on, a lot of potential contracts, but that business is not yet in. So I think it's going to be better next year, but I cannot tell when.
Tycho Peterson – JPMorgan
Okay. Thank you very much.
Our next question will come from Isaac Ro with Leerink Swann.
Isaac Ro – Leerink Swann
Hi, good afternoon. Thank you for taking the questions.
Martin Madaus
Charlie Wagner
Hi, Isaac.
Isaac Ro – Leerink Swann
Hey, how are you? First item would be on just sort of thinking about some of the new manufacturing facilities that we've seen in biotech in the last few weeks and months, both the monoclonals and vaccines. I'm wondering if – when these types of events happen, if there are any sort of meaningful startup costs or initial stocking events for your types of products that benefit your business? And if so, does that create maybe a tough comp in 2010 and the back half or the middle part of the year?
Martin Madaus
This is a good question, and we are watching stocking levels like hawks based on our experience with that. We don't see any increase in inventories at the major customers. I think that would lead us to believe this is significant and could be a challenge next year. I mentioned earlier that just the volume of vaccine production is much higher than usual, so some of that will not repeat. But at the same time, we have some template wins and we have some new molecules that are being produced. So I think overall, our mix of businesses between monoclonals, classic pharma, vaccine and plasma is very healthy. So we don't think it would be a challenge next year.
Isaac Ro – Leerink Swann
Great. And then just secondly, maybe a slightly different way to ask a similar question. You guys are obviously doing a good job controlling your working capital items. And I'm wondering – can you speak to the type of changes that you see either systemically or at least temporarily with both biotech and pharma customers on their own working capital items and to the extent that that might impact your own visibility?
Martin Madaus
There is more openness with large companies to collaborate as a strategic supplier. So, sharing information on demand. That is definitely better, and it's happening – starting to happen on a global basis. As you know, we are a strategic supplier to all these customers, but we haven't seen any different behavior right now. The only major shift, I would say, in the pharmaceutical and biotech industry is that the formally classical pharma companies are all basically investing through acquisitions or through R&D – their own R&D into biotech, which is a good thing. So whether it's Eli Lilly or Merck or Pfizer, everyone is looking at biotech. And we see that in the drug pipeline and drug discovery, and that's one reason why our drug discovery business that does exclusively biotech is growing very well. So there is a shift going on right now into biotech, which is very good for us.
Isaac Ro – Leerink Swann
Great. And then last question would be just sort of putting the vaccine item that you mentioned aside for a minute and looking at the totality of the late state pipeline for biotech, how would you say you feel about – we see some good data out of various drugs of importance in recent months. Would you say that you are probably more comfortable with the total pipeline now than you were maybe six months ago?
Martin Madaus
Yes. I think there is a marked improvement. We track, as you know, all the molecules, and that's why we are fairly comfortable and confident about the next wave of molecules, and our contribution and resulting growth from that.
Isaac Ro – Leerink Swann
Great. Thank you very much.
(Operator instructions) And our next question will come from Marshall Urist with Morgan Stanley.
Marshall Urist – Morgan Stanley
Hey, guys, good evening.
Martin Madaus
Good evening.
Marshall Urist – Morgan Stanley
One question on SG&A levels. Obviously your business seems like going one that would have a pretty good amount of SG&A leverage year-on-year. So I'm wondering if you could just give us a sense of where the infrastructure is and how you see that playing out over the next few years. And can we look (inaudible) that piece of the income statement? Thanks.
Martin Madaus
We will – we see modest leverage from SG&A, nothing major. But we see continued modest leverage from SG&A like we've seen in the past. And as we alluded to earlier, we will take some of that and invest into R&D at a little bit faster rate than SG&A.
Joshua Young
Marshall, I want to have to ask you to mute your phone after this next question if you have any other remaining questions. Okay. Operator, if you could go to the next question in the queue?
Our next question will come from Jon Groberg with Macquarie Capital.
Jon Groberg – Macquarie Capital
Hi, good evening. Thanks for taking the call.
Martin Madaus
Good evening.
Jon Groberg – Macquarie Capital
Martin, first from a couple of – maybe just kind of along the lines what you are saying in Asia, but I've heard from some players out there that some people are looking at being able to manufacture vaccines and biologics is almost a matter of national defense. And so you're going to see some of these countries like – particularly the big ones, if you think about the BRICK countries, but a lot of other countries actually, build out so they have the capabilities. Is that something you are seeing at all or hearing?
Martin Madaus
Yes, that's correct. In fact, when you look at a very large country like China, their population versus their vaccine manufacturing capability is way, way undersized. And as we see more – more focus now in these countries and also more money going into health care, developing vaccines is always a matter of public health and a priority. So I would very much expect as the technology becomes more available and skills are being built that these countries will absolutely invest into vaccines. I don't think they want to buy them from Western companies all the time.
Jon Groberg – Macquarie Capital
Would you have any – is this something you think as imminent? Is this five years out or –?
Martin Madaus
That – it takes a few years to build vaccine capabilities. That's for sure. And it will be helped also by multinationals who are making investments at the same time. But I think it's vaccine, but it's also I think for us, in one-year term, is the pharma. The injectable pharmaceuticals are very strong in China. So from a business standpoint, that's what we are focusing on near-term and then it will be followed by probably vaccine.
Jon Groberg – Macquarie Capital
Okay. And then just another kind of broader question on Bioprocess. If you look at kind of the first nine months and you kind of average over 2008 and 2009, we obviously went through some of the inventory issues in 2008, but it's about 2% growth. It goes back a little bit to the inventory question. But would you expect as you move out into 2010, '11, to be able to continue at this 9% growth or do you think that this becomes more kind of maybe a mid-single digit growth business, as you look at the next year trends?
Martin Madaus
That's a good question. And of course, I would hate to have it in 2008, because we see it more as a – a very low – I mean, definitely below average year. And there were some special items going on there. 9% is probably too high, but I think you're right about the mid-single digit is on a business of about $900 million would be a very good rate for us.
Jon Groberg – Macquarie Capital
Okay. And then last question, Charlie, can you just describe – I know on the Guava, because you were selling in the second half of last year, you now are including in your organic growth. But how is it accounted for in 2008? Did you account the whole sale, just the distributor margin, or can you maybe just describe how that works and just so we can understand kind of a year-over-year basis?
Charlie Wagner
Sure, yes. We started selling it in Q3 of 2008, although I think there were almost no revenues in Q3. They were very modest. So it really only affected Q4. And it was the full revenue on the system sale from what we had in the partnership at that point, which was the ability to sell into academic accounts. When we completed the acquisition, we gained obviously the ability to sell into all accounts. And so the way we looked at it this year was rather than trying to track the revenue, go back to the customer level and segment out which came from academic and which came from pharma and other accounts to do the organic/inorganic calculation that way. We just simply took all the first half revenue this year and excluded it from the organic growth rate, and we will take all the second half revenue this year and include it in the organic revenue growth rate. It's really unique to this transaction. We wouldn't normally do that, but it's because of the partnership set up from last year.
Our next question will come from Dan Leonard with First Analysis.
Dan Leonard – First Analysis
Thank you. You mentioned that you are making a lot of investments in the back half of the year. I'm curious in your investments in the Bioscience business, are you investing more in products that would be used in an academic environment as opposed to pharma? Or is there no discernible customer mix?
Martin Madaus
The investments are in both divisions, I would say. And in the Bioscience Division, say, you're correct. It's a higher investment of products going into products that will be used predominantly by researchers in academic settings. It could also be used in pharma, but we have a big focus on that. I think we are also investing into our lab water new product offering, which go into a variety of settings, including research but not exclusively. It goes very broad. And then on the Bioprocess side, all the products that we're developing, I mean, predominantly go into biopharmaceutical right now. And that's also a major push.
Dan Leonard – First Analysis
Okay. I guess what I was trying to get at is your investment to bioscience. Is there any – maybe more of a preference to be in academic and in pharma, or is that just what you see, maybe the biggest opportunity for your skill set?
Martin Madaus
For more the latter, more the biggest opportunity and skill set. But we have invested into drug discovery for biotech this quarter by making this bolt-on acquisition. So we do believe that pharma will come back and will be a good market over time.
Dan Leonard – First Analysis
Okay. And then a question for Charlie on the working capital. Charlie, the improvement in the quarter really seems to be – the biggest driver seems to be coming from the large increase in accruals. Is that something I should assume reverses in the next question?
Charlie Wagner
Yes, that's definitely a part of the story. Q3 was very strong overall driven by profits and improvements and receivables and inventory. But there were also some timing differences, things like pension payments and tax payments and so on that were very positive in the third quarter. They reversed in the fourth quarter, absolutely.
Dan Leonard – First Analysis
Yes. And then finally for BioAnaLab, should we expect meaningful sales from that going forward or now?
Charlie Wagner
Yes, absolutely. I mean, we didn't have it for much of the quarter, and we are going through the integration process right now. It will be meaningful in 2010.
Dan Leonard – First Analysis
What's the annual run rate?
Charlie Wagner
We're not breaking that out right now.
Dan Leonard – First Analysis
Okay. Thank you.
(Operator instructions) And our next question will come from Peter Lawson with Thomas Weisel Partners.
Eric – Thomas Weisel Partners
It's actually Eric [ph] filling in for Peter. I was wondering if you could maybe talk about that R&D, increasing investments and how you see it going forward. Is it still ramping up or is it hitting a steady growth rate or a plateau level?
Martin Madaus
It depends a bit on the projects that we need to fund. So we can – as I mentioned, we can increase R&D expenditures because we have the capability today financially. I would say, more importantly, we have really great projects that we would call breakthrough innovation projects that we can invest into. And I will always try to find a way to fund these projects if at all possible because I really believe that drives our business. So I don't want to say that R&D will grow at 15%. That's obviously a very high rate. It's 9% year-to-date. But we have – let's say, when you benchmark us against other companies, we have still some room to grow our R&D versus sales ratio. So it's more driven by the opportunities we see than just a strict financial ratio. Having said that, it's all within the means of what we will deliver in terms of earnings growth and cash flow.
Eric – Thomas Weisel Partners
Okay. And then on your diagnostics business, can you maybe talk a little bit about the strategy you have for that overall? I mean, is that something that you want to expand as you go or is it just something that's a nice business to have and you're kind of happy with where it is?
Martin Madaus
Yes, it's more the latter. It's a nice business we have. We have good success with that product line, but it's not part of our overall strategic thrust at this time.
Eric – Thomas Weisel Partners
Okay. And then just lastly, regarding the Asian build-out that you are kind of involved with, is that helping lab water in any way? I know you said that the instrumentation for lab water is kind of down in, say, the US and Europe maybe. But, is the Asian build-out kind of helping that growth out a little?
Martin Madaus
Yes, it does. It has always been a very strong part of the lab water business. Today it's already – Asia is (inaudible) much bigger than for the other business. And it's just a much better market growth and that growth is driven by lab expansions that are happening in those countries and we benefit from that. So we remain very important for lab water, and we are very active in that market. So particularly, China is a very big market for our lab water business.
Eric – Thomas Weisel Partners
Great, thanks.
Ladies and gentlemen, that's all the time we have allotted for today's call. I will now turn the call back over to Mr. Martin Madaus for closing remarks.
Martin Madaus
So, thank you for joining us this evening. I'm pleased that once again we are able to report very positive news to our investors. We will be attending two investor conferences during the fourth quarter. Hope that you will have a chance to interact with many of us at those venues. We are presenting at the CSFB Healthcare Conference in Phoenix, Arizona, that is on November 11th, and at the Deutsche Conference in Boston on December 10th. If you're interested in meeting with us, please contact Joshua Young. Thank you. Good night. Thank you for your attention. Have a good evening.
Ladies and gentlemen, this does conclude today's conference call. Thank you for your participation. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
What is the Auerbach Foundation?
The Auerbach Foundation was set up in April 2005 by Tjark Auerbach. He is an associate partner in the Avira company. The Auerbach Foundation supports projects in Germany, Austria and Switzerland. The main focus is set on Education, as well as Children, Youth & Family Welfare.
From the sale of every product for private users bought in the Avira online shop 5,00 € go straight into the Auerbach Foundation. The disclosed amount of 5,00 € for the Auerbach Foundation is a pure formality. Avira omitted voluntarily to 5,00 € from the proceeds.
This amount is a contribution to the Auerbach Foundation. This funding is clearly defined within the buying process in the Avira online shop and reported as such.
The Auerbach Foundation is not a corporate foundation of Avira. It is connected only through a grant agreement with Avira. For more information, please visit the Auerbach Foundation.
Affected products
- Avira Antivirus Pro - Business Edition [Windows]
- Avira Internet Security Suite [Windows]
- Avira Ultimate Protection Suite [Windows]
- Created : Wednesday, March 14, 2007
- Last updated: Wednesday, September 9, 2015


text:
Samson Dubina Sept. 13, 2016
Winning tournaments primary consists of playing your best while adjusting your tactics based on your opponent's strengths, weaknesses, and overall playing style.
Butterfly MDTTC September Open
Larry Hodges Sept. 13, 2016
New MDTTC coach Zhang Yan, unrated but seeded at what turned out to be an under-rated 2550, took top honors, defeating fellow MDTTC coach Chen Bo Wen ("Bowen," 2563) in the final, 11,3,-10,6,11.
Chinese Community Center once again proves ideal host
Ian Marshall/ITTF Sept. 13, 2016
Situated in Flushing, New York; the Chinese Community Center was the home for an ITTF/PTT Level One Course from Monday 29th August to Friday 2nd September.
North American Championships
USATT Sept. 13, 2016
USA defeats Canada in both Men's and Women's Teams, and so Team USA will represent North America at the 2017 World Team Cup.
2016 Thailand National Junior + Cadet Training Camp
Richard McAfee Sept. 13, 2016
20 Athletes Preparing for the Asian Junior and Cadet Championships. Eleven Coaches working the camp including 8 from the ITTF Level 2 Course.
Maximizing Benefits from Multiball Training in Table Tennis
Matt Hetherington Sept. 13, 2016
The topic of multiball came from a good friend of mine and player/coach from New Zealand who wanted to know my thoughts about multiball feeding when coaching.
5 Steps for Mastering Service Deception in Table Tennis
Matt Hetherington Sept. 13, 2016
The serve is so important in establishing a foothold in a table tennis match that making it as difficult to read as possible is crucially important, this blog will offer some tips as to how you can increase that difficulty level.
Revelations of a Table Tennis Champion by Dan Seemiller
Larry Hodges Sept. 13, 2016
It's out! Revelations of a Table Tennis Champion is the autobiography of five-time U.S. Men's Singles Champion Dan Seemiller (who along the way also won Men's Doubles 12 times, Mixed Doubles seven times, and was the U.S. Men's Coach at the Worlds and Olympics for many years).
Egypt's armless table tennis 'legend' is in a class apart
Sebastian Smith Sept. 13, 2016
Egypt's Ibrahim Hamadtou can swing a table tennis racket as well as the next Paralympian, but that's not what makes him a sensation: Hamadtou holds the racket between his teeth.
Paralympics Will Bayley wins table tennis gold and celebrates in style
Belfast Telegraph Sept. 13, 2016
Table tennis star Will Bayley won gold in the Class 7 singles at the 2016 Rio Paralympics, four years after winning silver at London 2012.


text:
Problem with my Ram
Hey guys Im new to this site to see if I can find some advice on what might be the problem with my truck. I was driving my truck one day and the truck randomly died on me and would not start up for about 5 minutes, so I figured that if I change the fuel pump that would solve the problem. After I changed the fuel pump the truck stopped dying on me, but the truck is now bogging, and back firing through the intake, and out the exhaust. I have changed the spark plugs, wires O2 sensors, and punched the cat, and nothing is working to fix this problem. I drive a 1998 Ram 1500 5.2L RWD, and I am hoping that someone here has the answer for me to fix this problem, please comment or private message me what you think and reasons that it would cause this problem Thanks alot.:smiley_thumbs_up:
2nd gen rams are good for fuel pump issues. bc of the collapsible pump. could maybe just be fuel pump again
Problem with my Ram
I was thinking that as well because were the sock is on the pump its located on the bottom of the pump so I was thinking maybe the pump is sitting on the bottom of the tank and not letting fuel pump up, could that be possible ?:doh:
could also be stuck at the top and extending/retracting back down to the bottom. the fuel pump is retractable like the little kid light swords lol. might be getting stuck
does it happen with a full tank of gas?
I havent tried it with a full tank of gas, because if it still does it thats gonna be a b*tch to change the pump, i have a new one on order and im going to try that first off
Not sure if this would be a similar issue or not but I had a 97 dodge ram SS/T , that did the same thing outa the blue in 2006 , found out it was bad fuel , dealer emptied the gas tank and we refilled with premium and never had a issue again , when it happen I changed pump , battery , spark plugs ect. to no avail finally went to dealership and tada changed the gas out and no issues after that
Problem with my Ram
really, never thought, that would cause it to back fire and all this sh*t to happen. maybe ill empty the tank into a jerry can and go grab some new stuff and try that out, im getting a new pump tomorrow because Ive heard from some people now including on this site that there was a bad batch of pump made awhile ago and the garage i heard this from had the same problem when they were installing them, and during the time it was happening to them they switched their supplier and they never had the problem again. Thanks alot guys hopefully both these suggestions fix this problem will repost tomorrow and let you know if it works.
Try checking your crankshaft position sensor had same issue with the 95 dodge ram i had would suddenly stall truck and or back fire found out the sensor was just giving a faulty signal replaced and it went back to normal
Any update on how things are working out??
|All times are GMT -4. The time now is 12:03 AM.
Powered by vBulletin® Version 3.8.10 Beta 2
Copyright ©2000 - 2016, vBulletin Solutions, Inc.
= Copyright RamForumZ.com a Gigathreads.com Network Site =Ad Management by RedTyger


text:
March 24th, 2011
Weegee the photographers as a Baby? I imagine this is how it would look.
Filed under: About Other ArtistsRead This Post
November 4th, 2010
Screen captures of every instance of a Speed Graphic type large format press camera in film or television that I can get my hands on.
Filed under: Photography in Movies and TelevisionRead This Post
August 2nd, 2010
Al Franken came to Duluth. I got photos.
Filed under: JournalRead This Post
October 10th, 2009
Although they have been obsolete for some time, does the large format press camera still have influence over people?
Filed under: Street EncountersRead This Post
August 21st, 2009
Dig deep into any of the many photography forums out on The Internets, and eventually you'll find a thread where everyone lists out of cameras which they have spotted in various films & television shows. The M3 in Coraline. Will Smith's ranegfinder in the title sequence of the Fresh Price of Bel-Air. They all get […]
Filed under: JournalRead This Post
July 1st, 2009
Sharing stories of the conversations that happen after being busted while doing street photography.
Filed under: Street EncountersRead This Post
April 20th, 2009
Graflex Camera ad. c. 1950
Filed under: Vintage MediaRead This Post
June 21st, 2008
Seven hours of my feet. 18 photos with the Speed Graphic. 72 Photos with the 124G. 96 Color photos with my M3. 128 B&W photos with my M3. Longest single outing I think I've ever had, and the first where I got to wear an actual badge saying "Official Photographer" and I'm surprisingly not as […]
Filed under: JournalRead This Post
May 31st, 2008
As promised, here are my results from the Duluth Classic bike race. Full set of keepers can be viewed in this set on my flickr page. More photos by clicking here.
Filed under: JournalRead This Post
June 10th, 2007
About fifteen minutes ago I was out doing some night photography with my Speed Graphic. The main part of the scene metered at 5:30 minutes exposure after factoring in reciprocity. The darkest parts that I wanted to register where pretty dark, so I needed to use my flash to build up some density. I opened […]
Filed under: JournalRead This Post


text:
News By Tag
Industry News
News By Location
Industry News
CC's Celebrations & More is Wedding Wire Rated for 2012
Apple Valley, CA – June 25, 2012 – WeddingWire is excited to announce that CC's Celebrations & More is WeddingWire Rated in 2012 for Wedding Planning.
"We are very pleased to announce WeddingWire Rated 2012, recognizing CC's Celebrations & More for their commitment to exemplary service in Wedding Planning," said Timothy Chi, CEO, WeddingWire, Inc. "CC's Celebrations & More has shown dedication to their craft and service, helping engaged couples understand what to expect from their business through reviews on the nation's leading wedding review site."
As the largest site for wedding reviews, WeddingWire empowers engaged couples with the most comprehensive and trusted review system available in the wedding industry. WeddingWire Rated provides CC's Celebrations & More with the distinction of being WeddingWire Rated and a simple platform to capture client feedback from their wedding planning experience. Engaged couples can easily access all of the reviews for CC's Celebrations & More on WeddingWire.com. We have all of our newlywed clients to thank for our WeddingWire Rated 2012 recognition.
WeddingWire Rated is the annual ratings program that recognizes wedding professionals across the country for their commitment to service and is the most recognized and trusted brand among engaged couples, as they start their search for local wedding businesses. The ratings program is based on hundreds of thousands of recent newlywed reviews of over 200,000 wedding professionals in the US and Canada, across 20 different service categories.For more information, please visit CC's Celebrations & More on WeddingWire at www.weddingwire.com/
About WeddingWire, Inc.
WeddingWire, the nation's leading marketplace serving the $70 billion wedding industry, is the only online wedding planning resource designed to empower both engaged couples and wedding professionals. For engaged couples, WeddingWire offers the ability to search, compare and book over 200,000 local wedding vendors, from wedding venues to wedding photographers. WeddingWire also offers an online community and a suite of cutting-edge planning tools for weddings, including wedding websites and wedding checklists, all at no charge. For wedding professionals, WeddingWire is the only all-in-one marketing platform for businesses online and on-the-go. WeddingWire offers one simple solution to build a professional network, improve search visibility, manage social media and reach mobile consumers. Businesses that advertise with WeddingWire appear on WeddingWire.com, ProjectWedding.com and other leading sites, including MarthaStewartWeddings.com, Brides.com and Weddingbee.com.
Account Email Address Account Phone Number Disclaimer Report Abuse


text:
Top Definition
–adjective swanky; elegant; posh: a ritzy neighborhood; a ritzy hotel. After the Ritz hotel. A very illustrious description of someone or something.
Those people at the party were just to ritzy for me. That hotel was just way to ritzy for me, im going to motel 6.
بواسطة Jeremy Hasenbuhler مارس/آذَار 26, 2007
Trending Now
Can you define these popular missing words?
really fancy
MAN 1- hey that tie really makes you look ritzy
MAN 2-thanks
MAN 2-thanks
بواسطة thegr8tman يناير/كانون الثّاني 15, 2012


text:
PHP/CURL Examples Collection
We try to collect examples on how to program the PHP/CURL interface here. If you have any source snippests you want to share with the rest of the world, please let us know!
|Post a blog entry to blogger.com using their "Atom" XML-based API.
|Michael Phipps
|Set callback functions to receive the HTTP response as it comes through.
|Keyvan Minoukadeh
|Login to on one page and then get another page passing all cookies from the first page along
|CURLOPT_CUSTOMREQUEST usage shown
|Mimics a browser and logs in to ebay
|Imran Khalid
|FTP upload to a remote site
|Daniel Stenberg
|Get the contents of a web page as a binary into a php variable.
|Get the contents of a remote web page into a PHP variable
|This code posts all the correct post fields to Googles universal Account Services login and brings the user directly to the AdSense Overview page. Cookies are used in this example as well as setting the USER AGENT and REFERRER HTTP headers.
|Shows how to submit and upload a file to a HTML upload form.
|Daniel Stenberg
|Check for a given link in a remote page
|Michael Phipps
|Shows how to fetch several documents at once by using the multi interface
|Roman Rozanov
|Using a multipart/form-post file upload form on a web page.
|Pete James
|Perform a HTTP PUT to a remote site
|Julian Bond
|Download a remote image, resize it and show it to the user
|Michael Phipps
|Follow your Adsense earnings with an RSS reader
|Get a URL
|Basic HTTP POST operation
The blogpost.php ExamplePost a blog entry to blogger.com using their "Atom" XML-based API. Written by Michael Phipps
<?php /* POST TO BLOGGER USING PHP AND CURL Before you can use this script, you need a blogger acocunt. They're free - go to http://blogger.com You need to have a blog that you can post to. You need to know the blogid of the blog you want to post to. To get the blogid, go to blogger.com and log in to your blogger account. There will be a list of blogs. When you click on a blog name, it will go to a url like : http://www.blogger.com/posts.g?blogID=1234567 The blogID portion is what you use for your $blog_id - in the above example it is 1234567 To carry out other blogger tasks, refer to the Atom API Documentation for Blogger: http://code.blogger.com/archives/atom-docs.html#authentication */ // Set the date of your post $issued=gmdate("Y-m-d\TH:i:s\Z", time()); // Set the title of your post $title="TEST ATOM API POST"; // Set the body text of your post. $body="This is a test post, sent using the atom api."; // This needs to be changed to the blogID of the blog // you want to post to (as discussed at the top of this script) $blog_id="1234567"; // You must know your username and password // to be able to post to your blog. $your_username="username"; //change this to your blogger login username $your_password="password"; // change this to your blogger login password // This is the xml message that contains the information you are posting // to your blog $content = "<?xml version='1.0' encoding='UTF-8' standalone='yes'?>\r\n" . "<entry xmlns='http://purl.org/atom/ns#'>\r\n" . "<title mode='escaped' type='text/plain'>".$title."</title>\r\n" . "<issued>".$issued."</issued>\r\n" . "<generator url='http://www.yoursitesurlhere.com'>Your client's name here.</generator>\r\n" . "<content type='application/xhtml+xml'>\r\n" . "
".$body."
\r\n" . "</content>\r\n" . "</entry>\r\n"; // This is the custom header that needs to be sent to post to your blog. $headers = array( "Content-type: application/atom+xml" ); // Use curl to post to your blog. $ch = curl_init(); curl_setopt($ch, CURLOPT_URL, "https://www.blogger.com/atom/".$blog_id); curl_setopt($ch, CURLOPT_RETURNTRANSFER, 1); curl_setopt($ch, CURLOPT_TIMEOUT, 4); curl_setopt($ch, CURLOPT_HTTPHEADER, $headers); curl_setopt($ch, CURLOPT_USERPWD, $your_username.':'.$your_password); curl_setopt($ch, CURLOPT_POSTFIELDS, $content); $data = curl_exec($ch); if (curl_errno($ch)) { print curl_error($ch); } else { curl_close($ch); } // $data contains the result of the post... echo $data; ?>


text:
I don't know why this keep happening to me? I found this new IEM co. during a search (HERE).
post #1 of 22
1/28/08 at 6:53pm
Thread Starter
Thank you for your inquiry submission to Microsonic Music. To get fitted for our custom monitors we recommend you to please visit one of our preferred dealers in your area. On our website there is a link that will help you locate a dealer near you. The cost of the custom monitor is $375.00.
Best Regards,


text:
In the aftermath of the Sandy Hook School shootings in Newtown, Connecticut, everyone was trying to find a way to understand what caused the massacre. Too many guns? Not enough guns? Mental health issues? All of the above. Here's my analysis for Yahoo! News...
As a journalist who grew up reading the New York Times -- and as a woman whose interest in news and writing inspired her to become a journalist -- I've been following the coverage of Jill Abramson's firing closely, looking for clues about why she was kicked...
Yes, that's a cow on the cover, serenely jumping over a split-log rail. When National Geographic Kids named their latest animal offering "125 True Stories of Amazing Pets," they weren't kidding about the "amazing" part. The book, with its bright-yellow bord...
FTC Statement I am not compensated for book, restaurant, or product reviews published here or at Worth Getting ,
my product review blog. Items are either purchased by me or are samples
are provided by the company and sent to me for evaluation. Samples
Back in Nov. 2011, I sat down with First Lady Michelle Obama and Dr. Jill Biden for an on-camera interview for Yahoo! News. Our conversation touched on several topics, from what it's like to raise kids in the public eye, why they're focusing on help for mil...
I'll just say it: I am scared of guns. At least, I used to be. Back in 2012 I finally decided to try to figure out why; I came up with a host of reasons/excuses, not a single one of which was based on any experience that I'd actually had myself. So I decide...
As a journalist who grew up reading the New York Times -- and as a woman whose interest in news and writing inspired her to become a journalist -- I've been following the coverage of Jill Abramson's firing closely, looking for clues about why she was kicked...
Over at U.S. News & World Report I've been wading deep into the STEM debate, overseeing our reporting on Science, Technology, Engineering and Mathematics education and employment, coordinating coverage of our annual STEM Solutions Conference , and launchin...
The Monster 600XL vacuum system. The Monster 600XL is a 3-in-1 vacuum system made up of a
hand-held, corded (not cordless) 600-watt motor, a crevice tool, an
upholstery/pet tool, a wheeled floor tool, a flexible extension hose, a
blower accessory, adapte...
Back in Nov. 2011, I sat down with First Lady Michelle Obama and Dr. Jill Biden for an on-camera interview for Yahoo! News. Our conversation touched on several topics, from what it's like to raise kids in the public eye, why they're focusing on help for mil...
Lylah M. Alphonse is Managing Editor for News at U.S. News & World Report. When she's not glued to the computer or solving a kid-related crisis, she's in the kitchen or, occasionally, asleep. Want more information? Visit her online at www.LylahMAlphonse.com, on LinkedIn, or on Twitter at @WriteEditRepeat.
- US News & World ReportManaging Editor/News, 2013 - present
- Yahoo.comSenior Editor, 2010 - 2013
- The Boston GlobeEditor, Writer, 1994 - 2010
Inside U.S. News and World Report with Managing Editor Lylah Alphonse - ...
Data journalism is a major focus in the U.S. News and World Report newsroom.
The Beatles Discography: Album by Album
A look at how the Beatles' music evolved from their first record to their last.
The War on Poverty, 50 Years Later
Overall, liberals and conservatives are still debating whether Johnson's War on Poverty was a success or a failure. Actually, it was both.
Going From Middle Class to Poverty
One man shares his story about joining the ranks of the working poor.
Be the Best You: 5 Steps to Better New Year's Resolutions
Tips for making New Year's Resolutions you're more likely to keep.
Murderabilia: When Does a Fascination With Crime Go Too Far?
Inside the minds of those involved in collecting and selling murderabilia.
VIDEO: Hospital Experts Talk About Prepping for Disasters
At the U.S. News Hospital of Tomorrow Forum, industry experts shared their insights about coping with crises (VIDEO).
How 'The Sound of Music' Went From Stage to Screen to NBC Special
'The Sound of Music' saw many forms before it became a Carrie Underwood live broadcast.
What Happens When a Town's Only Hospital Shuts Down?
Health care economics, politics and demographics have triggered an epidemic of hospital closures around the country. And the trend is likely
Telemedicine: Vast Potential, Increased Efficiency
At the U.S. News Hospital of Tomorrow conference, experts discuss the potential of telemedicine and what it means for the future.
Top Hospitals Opt Out of Obamacare
Americans who sign up for insurance on the state exchanges may not have access to the nation's top hospitals, Watchdog.org reports.
Community Health Centers: On the Front Lines of Obamacare
Community Health Centers provide services to more than 21 million Americans each year. Once more people have health insurance, that number w
Democrats Ask to Delay Obamacare Deadline
House and Senate Democrats call for delay in the deadline for the individual mandate.
Collectively, Not a Bargain for America
Are teachers unions and collective bargaining bad for STEM education? One technology expert shares his opinion.
Obamacare Premiums Lower than Projected, HHS Reveals
A new report shows average premium rates for health insurance marketplaces in 36 states would be lower than projected.
What You Need to Know About Health Insurance Exchanges
Experts offer consumers advice about heath insurance marketplaces.
ACA Roundup: Young Invincibles Want Health Insurance, Study Show
Recent news about the Affordable Care Act and its impact on consumers.
Study: Some Families Could Be Forced to Repay ACA Subsidies
A new study suggests that, for many families, the Affordable Care Act (ACA) will be less affordable than they expect.
New Monitoring System Improves Patient Comfort and Care
The device, made by EarlySense, slips under the mattress instead of attaching to the patient, cutting back on false alarms.
ACOs Try to Solve the Post-Acute Care Crisis
Five competing accountable care organizations in Massachusetts are working together to reduce problems that crop up for patients who require